Megacard

Megacard Uses, Dosage, Side Effects, Food Interaction and all others data.

Megacard are prescription drugs that contain eicosapentaenoic acid-ethyl ester (EPA) and docosahexaenoic acid-ethyl ester (DHA) that are used in combination with changes in diet to lower triglyceride levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia. Megacard are currently marketed in the US, EU, and many other regions under the brand name Lovaza.

Megacard reduce triglyceride production, increase fatty acid metabolism, inhibit the release of fatty acids, increase triglyceride clearance, and decrease production of very low density lipoprotein cholesterol(VLDL-C).

Trade Name Megacard
Generic Omega-3-acid ethyl esters
Omega-3-acid ethyl esters Other Names Omega-3 fatty acid ethyl esters, Omega-3-acid ethyl esters
Type Capsule
Protein binding

Because omega-3-acid ethyl esters are rapidly hydrolysed and incorporated into other processes and structures, protein binding data is scarce. However, most of EPA is bound to plasma protein.

Groups Approved, Investigational
Therapeutic Class
Manufacturer Mission Pharmaceuticals
Available Country Pakistan
Last Updated: September 19, 2023 at 7:00 am
Megacard
Megacard

Uses

Megacard is a mixture of fatty acids used as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.

Omega-3-Acid Ethyl Esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG).

Megacard is also used to associated treatment for these conditions: Severe Hypertriglyceridemia

How Megacard works

Megacard reduce triglyceride production by the liver but this mechanism is not well understood. Megacard inhibit acyl-CoA:1,2-diacylglycerol acyltransferase, reducing triglyceride synthesis and increasing paroxysmal beta-oxidation, which increases fatty aside metabolism. Megacard also inhibit the release of fatty acids by competing for enzymes involved in the synthesis of triglycerides, increase triglyceride clearance by increasing the activity of lipoprotein lipase, and decrease production of VLDL-C.

Toxicity

In rats, omega-3-acid ethyl esters are not mutagenic or clastogenic and do not lead to impairment of fertility.

Safety in human pregnancy have not been performed, however an embryocidal effect was seen in rats force fed 7 times the maximum recommended human dose. The risk and benefit of treatment during pregnancy should be weighed before deciding on treatment.

Animal studies in lactating rats have shown excretion of omega-3-acid ethyl esters at concentrations 6 to 14 times higher than in the serum of the mother, however the effects of this excretion on a mother or child have not been established.

Safety and effectiveness in pediatric patients has not been established.

There appear to be no differences in the safety and efficacy in patients above or below 60 years of age based on limited data.

Food Interaction

  • Take with a full glass of water.
  • Take with food. Take with food to reduce gastrointestinal disturbance.

Volume of Distribution

82 ± 56L

Elimination Route

Megacard are rapidly hydrolysed to free fatty acids in the intestinal lumen which then become incorporated into phospholipids, cholesterol, and triglycerides so determination of bioavailability by serum concentration is not possible.

Half Life

79 hours ± 47 hours.

Clearance

757 mL/h ± 283mL/h.

Elimination Route

Includes oxidative catabolism to carbon dioxide and water

Innovators Monograph

You find simplified version here Megacard

*** Taking medicines without doctor's advice can cause long-term problems.
Share